Chronic Rhinosinusitis Trial, Recruiting NCT05009758 Sponsor: Medical University of Vienna Condition: Chronic Rhinosinusitis
Back to Chronic Rhinosinusitis

Chronic Rhinosinusitis Trial, Recruiting

NCT05009758
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 99 years old
  • You have an official diagnosis of asthma recorded by a doctor
  • You are receiving treatment for moderate-to-severe asthma at a higher level of care (known as GINA/DAL step 4 or 5), but are NOT currently taking steroid tablets by mouth or biologic injection treatments
  • You have been on your current asthma treatment for at least 12 weeks before the first study visit
  • For Groups 1 & 2 (asthma with signs of type 2 inflammation, with or without nasal polyps): Your breathing test shows raised inflammation markers (FeNO above 25 ppb), AND your blood or mucus tests show higher-than-normal levels of a certain type of immune cell called eosinophils
  • For Group 2 only (asthma with nasal polyps): You have been confirmed to have nasal polyps through a scan or camera examination of your nose
  • For Group 3 (nasal polyps without asthma): You have confirmed nasal polyps (via scan or camera), blood test results showing signs of type 2 inflammation, and you do NOT have asthma or a condition called N-ERD
  • If you have previously been treated with a biologic (monoclonal antibody) for asthma or nasal polyps, at least 3 months or 5 half-lives of that medication must have passed since your last dose (confirm with trial site)

Who may not be able to join:

  • You are currently pregnant
  • You have physical nasal anatomy that would prevent a camera from reaching all parts of your nasal cavity
  • You are currently taking steroid tablets (such as prednisolone) on an ongoing basis
  • You have another serious lung condition such as bronchiectasis, COPD, pulmonary fibrosis, emphysema, cystic fibrosis, a parasitic lung infection, or lung cancer
  • You have a condition that causes asthma-like symptoms along with high eosinophil levels, such as EGPA, allergic bronchopulmonary aspergillosis, or hypereosinophilic syndrome (confirm with trial site)
  • You have a mental health condition that would make it difficult to fully understand what taking part in the study involves
  • You have another serious health condition that the study team decides could interfere with the trial (confirm with trial site)
  • You have had a flare-up of your sinusitis or asthma in the 4 weeks before any study visit
  • You have taken a short course of steroid tablets in the 4 weeks before any study visit
  • You are currently taking immunosuppressant medication (for example, cyclosporine)
  • You currently misuse drugs or alcohol
  • You are a current smoker
  • You are a former smoker who quit less than 6 months ago, or who smoked heavily for more than 10 pack-years (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Julia Eckl-Dorna, PhD, Medical University of Vienna

Phone: +4314040034380

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 September 2021
Est. completion
1 September 2025

Where this trial is recruiting

🇦🇹 Austria

Primary endpoints

Inflammatory profile in different sections of the airways

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov